Illumina (ILMN) Cash from Financing Activities (2009 - 2026)
Illumina's (ILMN) quarterly Cash from Financing Activities came in at -$129.0 million in Q2 2026, up 65.23% on a YoY basis from -$78.1 million in Q2 2025, and up 48.61% quarter-over-quarter from -$251.0 million in Q1 2026.
Analysis
Illumina (ILMN) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Illumina (ILMN) has reported Cash from Financing Activities for 18 consecutive years, with -$129.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities rose 65.23% year-over-year to -$129.0 million; the trailing twelve-month figure through Jun 2026 stood at -$558.0 million (up 40.95% YoY), and the FY2025 full-year result was -$744.0 million, down 30.53% from the prior year.
- Cash from Financing Activities improved to -$129.0 million in Q2 2026 per ILMN's latest filing, from -$251.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $922.0 million in Q1 2023 and bottomed at -$707.0 million in Q4 2023.
- Historically, Cash from Financing Activities has averaged -$122.6 million across 5 years, with a median of -$122.0 million in 2025.
- The widest YoY moves for Cash from Financing Activities: up 107.4% in 2024, down 7433.33% in 2024.
- Over 5 years, Cash from Financing Activities stood at $21.0 million in 2022, then plunged by 228.57% to -$27.0 million in 2023, then sank by 74.07% to -$47.0 million in 2024, then tumbled by 34.04% to -$63.0 million in 2025, then tumbled by 104.76% to -$129.0 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$129.0 million, -$251.0 million, and -$63.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | -1.57 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | 7.27 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | 471.00 Mn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | -129.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | -23.16 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | -33.21 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | -27.60 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | -6.20 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | 3.02 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | 149.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | -129.00 Mn |
| Mar 29, 2026 | -251.00 Mn |
| Dec 28, 2025 | -63.00 Mn |
| Sep 28, 2025 | -115.00 Mn |
| Jun 29, 2025 | -371.00 Mn |
| Mar 30, 2025 | -195.00 Mn |
| Dec 29, 2024 | -47.00 Mn |
| Sep 29, 2024 | -332.00 Mn |
| Jun 30, 2024 | -226.00 Mn |
| Mar 31, 2024 | 35.00 Mn |
| Dec 31, 2023 | -27.00 Mn |
| Oct 1, 2023 | -707.00 Mn |
| Jul 2, 2023 | -3.00 Mn |
| Apr 2, 2023 | -473.00 Mn |
| Jan 1, 2023 | 922.00 Mn |
| Apr 3, 2022 | 21.00 Mn |
| Oct 3, 2021 | -394.00 Mn |
| Jul 4, 2021 | -496.00 Mn |
| Apr 4, 2021 | 968.00 Mn |
| Jan 3, 2021 | -331.00 Mn |